Uncategorized

Shell (LSE: SHEL) and Equinor (OSE: EQNR) have announced plans to combine their North Sea oil and gas assets into a new company, set to become one of the largest producers in the region. The joint venture will be based in Aberdeen. The 50-50 partnership will incorporate Equinor’s holdings in Mariner, Rosebank, and Buzzard fields, […]

Mesoblast (ASX:MSB) has announced that the US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy designation to its Revascor (rexlemestrocel-L) drug for children with hypoplastic left heart syndrome (HLHS). This builds on earlier FDA designations of Rare Pediatric Disease (RPD) and Orphan-Drug (OD) status for the therapy. Mesoblast develops allogeneic (off-the-shelf) cellular medicines

Larvotto Resources (ASX:LRV) has announced a successful $30m equity raising through the placement of 57.7 million new shares at $0.52 each. This two-tranche placement saw strong support from both existing and new institutional investors. The funds, combined with $6.2m from a recently announced antimony prepayment facility and $8m from options conversion, bolster Larvotto’s ability to

Spartan Resources (ASX:SPR) has secured $220m in funding through an institutional placement to accelerate the restart of operations at its Dalgaranga Gold Project in Western Australia. The placement, conducted at $1.32 per share, received strong backing from domestic and international resource-focused investors. Notably, Ramelius Resources (ASX:RMS), Spartan’s largest shareholder, increased its stake to 19.9% through

HMC Capital has announced the acquisition of Neoen’s Victorian renewable energy portfolio for $950m, marking a step in its move into the energy transition sector. The portfolio includes 652MW of operational capacity across wind, solar, and battery energy storage systems (BESS), along with a 2.8GW development pipeline featuring advanced-stage projects. The purchase will seed HMC’s

INOVIQ (ASX:IIQ) has announced progress in breast cancer diagnostics, completing a pivotal study for its “neuCA15-3” blood test. The test is designed to detect breast cancer across all stages and major subtypes. It achieved 81% sensitivity (correctly identifying those with breast cancer) and 93% specificity (accurately excluding those without breast cancer).  INOVIQ is a biotech

Dr Shane Oliver, Head of Investment Strategy & Chief Economist at AMP, discusses key themes for 2024. Key points The key themes for 2024 were: better than feared growth; global divergence; more disinflation; falling interest rates but with Australia lagging; and more geopolitical threats but not as bad as feared. As in 2023, returns were

The S&P 500 and Nasdaq Composite surged to record highs on Wednesday, driven by strong reports from Salesforce and Marvell Technology, with tech stocks leading the rally. The broad market index rose 0.61 per cent, closing at 6,086.49, while the Nasdaq climbed 1.3 per cent to finish at 19,735.12. The Dow Jones Industrial Average gained

DroneShield (ASX:DRO) has announced a repeat order worth $8.2m from a major European military customer. The contract involves providing dismounted and vehicle-mounted counter-drone (Counter-UxS) systems, with delivery expected over the next three months, including from existing stock. Full cash payment is anticipated in Q1 2025. CEO Oleg Vornik commented: “Larger orders of this type from

Amazon Web Services (AWS) has announced plans to build what it claims will be the world’s largest artificial intelligence (AI) supercomputer. Dubbed Project Rainier, the supercomputer is expected to be operational by 2025. The announcement was made on 3 December at the AWS re:Invent conference in Las Vegas. The computer will be powered by AWS’s